Brokerage Firm Rating Update on Cerus Corporation (CERS)

Cerus Corporation (CERS) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 5 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Cerus Corporation (CERS) : The highest short term price target forecast on Cerus Corporation (CERS) is $10 and the lowest target price is $9. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $9.7 with a standard deviation of $0.45.


For this week, the average consensus of the company shares are rated as a Strong Buy.

Cerus Corporation (NASDAQ:CERS): The stock opened at $6.36 and touched an intraday high of $6.61 on Wednesday. During the day, the stock corrected to an intraday low of $6.35, however, the bulls stepped in and pushed the price higher to close in the green at $6.47 with a gain of 1.89% for the day. The total traded volume for the day was 980,980. The stock had closed at $6.35 in the previous trading session.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.